Stocks · News reference
Last patient completed final 72-week visit in NATiV3, with 1,009 patients enrolled in the main cohort and 410 patients in the exploratory cohortTopline results of NATiV3 expected in Q4 2026September investor conference
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Companies Reporting Before The Bell • Tamboran Resources (NYSE:TBN) is estimated to report quarterly loss at $0.30 per share on revenue of $3.82 million. Companies Reporting After The Bell • Inventiva (NASDAQ:IVA) is
U.S. futures rose, but Novo Nordisk fell 4.8% after Cagrisema trial results; Aligos, Telix and other stocks also dropped premarket.
Guggenheim analyst Seamus Fernandez maintains Inventiva (NASDAQ:IVA) with a Buy and raises the price target from $11 to $14.